EC metabolism is therefore proposed as a target combined with VEGF inhibitors to best normalize tumour vasculature by altering the temporal dynamics of differential adhesion and cell rearrangement, promoting branching rather than expansion. The gene discussed is VEGFA; the disease is neoplasm.